Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. - Wikidata - wikimedia - TriplyDB

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

http://www.wikidata.org/entity/Q39911338

about

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia Chronic myeloid leukemia: reminiscences and dreams The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL The emerging role of CaMKII in cancer Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations Affinity-Based Probes Based on Type II Kinase Inhibitors c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease Development of novel ACK1/TNK2 inhibitors using a fragment-based approach A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.A chemical and phosphoproteomic characterization of dasatinib action in lung cancer A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Chemical proteomics: terra incognita for novel drug target profiling.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Chemistry-based functional proteomics for drug target deconvolution.Control of mammary tumor differentiation by SKI-606 (bosutinib).Novel targeted therapies for eosinophil-associated diseases and allergy Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics Phosphoproteomics in cancer Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.Microfluidic whole blood testing of platelet response to pharmacological agents.Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.Activation of abl family kinases in solid tumors.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

P2860

Q24607114-9B63B704-6C78-46CD-9463-DF6C474D713B Q26748769-ABA31EEC-625B-4745-A40F-41A9E9EAFDBE Q26866312-6140D591-C5FE-4BC7-8FEF-D7E028A6A772 Q26995205-F540E42C-D6A0-4530-955E-A78B28736149 Q27004027-FA0F35FF-8561-4C79-83FC-6D8A03FC24DB Q27004032-6E2EFF5A-9818-433A-9534-58915A6B1AA6 Q27674665-E2F11B00-A0BC-4F76-A317-A8E82632EB55 Q28070292-647E7AA4-2FE7-488C-89E9-0F140F40F23E Q28257452-625195F3-462B-4CA3-8FF6-A2C0BF01DB11 Q28534337-27AE2331-4B5D-4A68-A4E3-F80BCC27FBD1 Q30243925-72F7B256-29C1-4126-A7A4-1CA203CDA3C0 Q30396736-E9F1F69E-987A-45AB-91A0-05EB05531B90 Q33414487-1C621B09-6F21-4B93-B0EE-79B15559F829 Q33434675-10A3A073-0ACE-4D17-BF68-E202E1953FDB Q33442587-8712096F-6098-4724-A9A3-BEF10EB18EE7 Q33584613-6C4F8CCB-B8FC-4FC1-A59F-7E2F461CFAD5 Q33742159-CAC10E3E-BD05-4A2B-B5DE-1C8C9EBD97CD Q34024820-66F00607-3851-476C-AE69-431E51B0504D Q34026441-E8F469AF-B9DE-407D-847A-3A8507FE0310 Q34121339-0C64C615-A18F-4B76-A650-0A94D5845748 Q34210528-AE0B638A-4D89-40F8-B313-87DCF0D1F949 Q34284580-1FCC88AA-437C-460A-B57D-DBBA11D5784C Q34297594-0A6F09A5-1D03-4B27-87CF-B2E71483F929 Q34342905-D46109A9-C8FB-4C64-B767-A4C91C35AA95 Q34398204-77D64E5B-EE1D-4203-BC56-8F7E3B91A254 Q34444620-B2DF73D1-0CFE-411E-A7DC-721145E88448 Q34458274-78D86898-E203-40C0-8B00-4F718B857D54 Q34539788-B2555ABF-9DAC-4A7B-8149-8EEBCC60D546 Q34763374-CF8950CC-1E47-4186-954B-BBDE2D139E45 Q35008618-45802F90-27F5-4DFC-8604-2EABD5272163 Q35743878-E24276D7-7ED5-49E8-B8AA-C2396DFF8B88 Q36169317-64FD9D40-0960-44E5-98EB-6905EF06ACF8 Q36253661-E301199E-4686-4C5A-9AE4-5E79C6CB6753 Q36270666-9C4290CE-6A0B-4D10-B944-C61D93777AD2 Q36386366-00AE0FE6-3FB7-48B0-9240-33067A57C83F Q36394668-9B9E4086-58F2-4498-9B33-D62456761F57 Q36443421-AF314F94-0AC3-4616-B8A1-E02251FD1A89 Q37027759-18FBCD2A-ACED-4AB4-9970-14DE81CF8982 Q37058890-0134AF76-948A-43B4-9BA3-E9F725822E77 Q37069163-69C74F38-5A4A-4460-95E2-8B35EA6DE7C6

P2860

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

http://www.wikidata.org/entity/Q39911338

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Global target profile of the k ...... hronic myeloid leukemia cells.

@en

Global target profile of the k ...... hronic myeloid leukemia cells.

@nl

type

label

Global target profile of the k ...... hronic myeloid leukemia cells.

@en

Global target profile of the k ...... hronic myeloid leukemia cells.

@nl

prefLabel

Global target profile of the k ...... hronic myeloid leukemia cells.

@en

Global target profile of the k ...... hronic myeloid leukemia cells.

@nl

P1433

Q39911338-CD276B52-BEAA-40C6-AF00-B8E1FBF0BC85

P1476

Q39911338-C450573F-4ABF-4D0C-885D-54BB2056D5A3

P2093

Q39911338-16207228-2B8D-4DE1-B1D3-B92192C15454

Q39911338-4908E30F-D5CC-41C5-BB0C-6531F642FC95

Q39911338-8BB3AB98-F3A3-4FA5-839A-BE205B945112

Q39911338-8C6A32E1-3CD4-413E-B563-EAE840E035A4

Q39911338-8D746CE3-C69A-43E8-8C70-566DB3C299F6

Q39911338-9FDA647F-1A82-48CE-B410-C71B86431A13

Q39911338-C602293D-A8A5-4CEC-9A88-30139BA4DA14

Q39911338-DB65DBC0-9A06-4022-B097-8A767FE0944C

Q39911338-EAE76BE0-481B-4D4A-ACDE-9084AAF7428A

Q39911338-EF21D24A-D080-411B-915D-2AA27D3F9B2B

P2860

Q39911338-1190E078-7420-4DFC-80CE-09753159C665

Q39911338-12267064-9C75-4501-A32B-4B34903B24FA

Q39911338-17939531-0410-4000-84C0-DE546391BDDA

Q39911338-2EE552FC-ABDD-4577-8752-7B22021CC44B

Q39911338-32349D19-33CC-4D8E-A5C0-FFBC4E5FB354

Q39911338-32C90C9F-4134-47B3-8594-8CD3C3ECE2E3

Q39911338-36D6A619-7347-4D76-AB6F-44D0F1F2A95B

Q39911338-399D3B23-E224-4A99-9A69-9ED75E90B14C

Q39911338-445964A0-1E44-494C-86F9-52DFD3859DB4

Q39911338-4FAD5E7C-657F-4FB1-8227-F57E07C8DB47

P2888

Q39911338-B139B141-CE77-41BE-83A9-78CAD755F32D

P304

Q39911338-9353F18D-6F4A-4DBE-94AB-499CE705CDD8

P31

Q39911338-B52F78DB-658C-4FA4-83F5-456839F338FF

P356

Q39911338-C9484CAB-EE33-4A7A-B640-75A3110F6B09

P433

Q39911338-2C42C72D-5682-4E94-8E78-D5F755C3112D

P478

Q39911338-8B641777-58F8-4008-A18E-52C7B062EC39

P50

Q39911338-0FDF047B-3579-4495-972F-A128F2B0696F

Q39911338-BF1629E3-92EF-481C-8BE6-B80B3EFEC10F

P577

Q39911338-A5266202-66E7-4D76-8583-E6F0008B78CB

P5875

Q39911338-BBD67699-82DC-4BD5-A09C-375962A8FEFD

P6179

Q39911338-B06715AE-49DC-448C-8970-7B169B85B086

P698

Q39911338-32BFBCF2-10F6-4274-AA0E-C6090E5B9A34

P921

Q39911338-1D8816CE-2E73-4605-BFCA-3741253B1710

Q39911338-EE5299DC-4475-48A9-B8E1-233776C509B3

Q39911338-FE52785D-F98A-437F-887E-7915DDD6BE77

P356

P1433

P1476

Global target profile of the k ...... hronic myeloid leukemia cells.

@en

P2093

A Müller

http://www.w3.org/2001/XMLSchema#string

C Baumgartner

http://www.w3.org/2001/XMLSchema#string

J Colinge

http://www.w3.org/2001/XMLSchema#string

J H Till

http://www.w3.org/2001/XMLSchema#string

K L Bennett

http://www.w3.org/2001/XMLSchema#string

L L Remsing Rix

http://www.w3.org/2001/XMLSchema#string

M Augustin

http://www.w3.org/2001/XMLSchema#string

P Valent

http://www.w3.org/2001/XMLSchema#string

T Stranzl

http://www.w3.org/2001/XMLSchema#string

U Rix

http://www.w3.org/2001/XMLSchema#string

P2860

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

EGFR antagonists in cancer treatment

A small molecule-kinase interaction map for clinical kinase inhibitors

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

P2888

P304

477-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2008.334

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Oliver Hantschel

Giulio Superti-Furga

P577

2008-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23503092

http://www.w3.org/2001/XMLSchema#string

P6179

1043735889

http://www.w3.org/2001/XMLSchema#string

P698

19039322

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia